OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be

Simply Wall St
May 11, 2022
Source: Shutterstock

The latest analyst coverage could presage a bad day for OSE Immunotherapeutics SA (EPA:OSE), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

Following the latest downgrade, the three analysts covering OSE Immunotherapeutics provided consensus estimates of €13m revenue in 2022, which would reflect a concerning 52% decline on its sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of €16m in 2022. It looks like forecasts have become a fair bit less optimistic on OSE Immunotherapeutics, given the pretty serious reduction to revenue estimates.

View our latest analysis for OSE Immunotherapeutics

ENXTPA:OSE Earnings and Revenue Growth May 11th 2022

Of course, another way to look at these forecasts is to place them into context against the industry itself. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 52% by the end of 2022. This indicates a significant reduction from annual growth of 17% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 34% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - OSE Immunotherapeutics is expected to lag the wider industry.

The Bottom Line

The most important thing to take away is that analysts cut their revenue estimates for this year. They're also anticipating slower revenue growth than the wider market. After a cut like that, investors could be forgiven for thinking analysts are a lot more bearish on OSE Immunotherapeutics, and a few readers might choose to steer clear of the stock.

But wait - there's more! We have estimates for OSE Immunotherapeutics from its three analysts out until 2024, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.